Start-Up Quarterly Statistics, Q1 2010
This article was originally published in Start Up
Highlights from the Q1 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $331 million, a 66% drop from the previous quarter's $976 million, and a 52% slide from Q1 2009. As was the case in Q4 2009, Series B rounds dominated in the biopharma and device sectors. Just one acquisition closed in the quarter - BioMarin buying LEAD Therapeutics - however two others are in the works. On the alliance front, SpePharm and Dicerna each signed two deals in Q1.
You may also be interested in...
Devicor Medical Products is seeking a foothold in the device market with its proposed acquisition of Johnson & Johnson/Ethicon Endo-Surgery's breast care business, the company announced March 30
Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.
As it looks for a new investor to lead its second round of funding, RNA interference start-up Dicerna Pharmaceuticals has signed its first big-pharma customer. Japan's Kyowa Hakko Kirin will pay $4 million up-front and as much as $120 million in milestones to develop therapeutics around an undisclosed solid-tumor cancer target using Dicerna's technology